Frank R. Cruz Law Offices Reminds Investors of Class Action Deadlines for BTGO, ERAS, NNOX, and MSFT

GlobeNewswire··Read original
2▲0 ▼4Impact / 5
Summary · why it matters

The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of BitGo Holdings, Erasca, Nano-X Imaging, and Microsoft, with lead plaintiff deadlines in August 2026. For BitGo, the class period runs from January 22, 2026 to May 13, 2026, with a deadline of August 7, 2026; the complaint alleges the company understated risks from declining digital asset prices. Erasca's class period is January 14, 2025 to April 26, 2026, with a deadline of August 10, 2026, and the suit claims preclinical data for ERAS-0015 was based on improper comparisons and risked patent violations. Nano-X Imaging faces a class period from March 31, 2025 to April 17, 2026, with a deadline of August 11, 2026, over allegations it overstated efficiency gains and demand while masking rising expenses and cash burn. Microsoft's class period is May 1, 2025 to January 28, 2026, also with an August 11, 2026 deadline, and the complaint alleges the company failed to disclose significant problems with its Copilot products, poor AI model benchmarks, and the need for billions in extra capital expenditures that diverted resources from Azure, leading to low paid subscription conversion and market share losses.

Impact on assets 4

Artificial Intelligence▼
Microsoft Corporation
MSFT
▼ NegativeTechnologyrelevance

Class action alleges Microsoft failed to disclose significant problems with Copilot products, poor AI model benchmarks, and low paid subscription conversion.

Nano X Imaging Ltd
NNOX
▼ NegativeDemandrelevance

Class action alleges Nano-X overstated efficiency gains and demand while masking rising expenses and cash burn.

Digital Finance & Tokenization▼
BitGo Holdings, Inc.
BTGO
▼ NegativeRegulationrelevance

Class action alleges BitGo understated risks from declining digital asset prices.

Biotech & Genomic Medicine▼
Erasca Inc
ERAS
▼ NegativeRegulationrelevance

Class action lawsuit alleges preclinical data for ERAS-0015 was based on improper comparisons and risked patent violations.